Simpson, Eric L. http://orcid.org/0000-0003-0853-0252
Prajapati, Vimal H. http://orcid.org/0000-0002-8315-2522
Leshem, Yael A. http://orcid.org/0000-0001-8740-9674
Chovatiya, Raj http://orcid.org/0000-0001-6510-399X
de Bruin-Weller, Marjolein S. http://orcid.org/0000-0002-1249-6993
Ständer, Sonja http://orcid.org/0000-0003-3612-7786
Pink, Andrew E. http://orcid.org/0000-0001-5151-5539
Calimlim, Brian M. http://orcid.org/0000-0002-6463-6433
Lee, Wan-Ju http://orcid.org/0000-0001-9263-6943
Teixeira, Henrique
Ladizinski, Barry http://orcid.org/0000-0001-7459-0830
Hu, Xiaofei http://orcid.org/0009-0009-1415-6843
Yang, Yang http://orcid.org/0000-0001-6705-8360
Liu, Yingyi http://orcid.org/0009-0002-5243-0793
Liu, Meng http://orcid.org/0009-0000-7517-1769
Grada, Ayman http://orcid.org/0000-0002-5321-0584
Platt, Andrew M. http://orcid.org/0009-0000-7950-2860
Silverberg, Jonathan I. http://orcid.org/0000-0003-3686-7805
Clinical trials referenced in this document:
Documents that mention this clinical trial
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
https://doi.org/10.1007/s13555-024-01157-5
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
https://doi.org/10.1007/s40257-024-00853-4
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01242-9
Documents that mention this clinical trial
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
https://doi.org/10.1007/s13555-024-01157-5
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
https://doi.org/10.1007/s40257-024-00853-4
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01242-9
Article History
Received: 8 February 2024
Accepted: 3 April 2024
First Online: 2 May 2024
Declarations
:
: Eric L. Simpson has received personal fees from AbbVie, Amgen, Arena Pharmaceuticals, ASLAN, Benevolent AI-Bio Tech Limited, BiomX Ltd, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, Coronado, Dermira, Evidera, Excerpta Medica, Galderma, GSK, Forte Biosciences, Incyte Dermatologics, Janssen, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Lilly, Medscape, Merck, Novartis, Ortho Galderma, Pfizer, Physicians World, Pierre Fabre Dermo Cosmetique, Regeneron, Roivant Sciences, Sanofi-Genzyme, SPARC India, Trevi therapeutics, WebMD, and Valeant. He has received grants from AbbVie, Amgen, Arcutis, ASLAN, Castle Biosciences, Celgene, CorEvitas, Dermavant, Dermira, Galderma, Incyte, Kymab, Kyowa Hakko Kirin, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, and TARGET-DERM outside the submitted work. Vimal H. Prajapati has served as an advisor, consultant, and/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Cipher, Eczema Society of Canada, Galderma, GSK, Homeocan, Janssen, LEO Pharma, Lilly, L’Oréal, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant. He has served as an investigator for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Nimbus Lakshmi, Novartis, Pfizer, Regeneron, Reistone, Sanofi Genzyme, Takeda, UCB, and Valeant. He has received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Yael A. Leshem has received honoraria or fees as a consultant from AbbVie, Genentech, Janssen, Pfizer, and Sanofi. She has served as an advisory board member for AbbVie, Dexcel Pharma, Pfizer, Regeneron, and Sanofi; has received an independent research grant from AbbVie; and has, without personal compensation, provided investigator services for AbbVie, Lilly, and Pfizer. Raj Chovatiya has served as an advisor, consultant, speaker, and/or investigator for AbbVie, Arcutis, Argenx, Apogee, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Galderma, Genentech, Incyte, LEO Pharma, Lilly, L’Oréal, Nektar, Novan, Inc., Opsidio, Pfizer, Regeneron, Sanofi, and UCB. Marjolein S. de Bruin-Weller is a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Amgen, Aslan, Galderma, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Sonja Ständer is an investigator for Celldex, Clexio, Galderma, GSK, Incyte, Kiniksa Pharmaceuticals, Menlo Therapeutics, Novartis, Sanofi Genzyme, and Trevi Therapeutics. She is a member of scientific advisory boards, consultant, and/or speakers’ bureaus for AbbVie, Almirall, Beiersdorf, Benevolent, Bionorica, Cara, Clexio Biosciences, Escient Pharmaceuticals, Galderma, Grünenthal, Kiniksa, Klinge Pharma, LEO Pharma, Lilly, Menlo Therapeutics, Pfizer, P.G. Unna Academy, Sanofi Genzyme, Symbio Research, Trevi Therapeutics, Vifor Pharma, and WebMD. Andrew E. Pink has been an advisor/speaker/investigator or has received educational support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, and Andrew M. Platt are full-time employees of AbbVie, and may hold AbbVie stock and/or stock options. Barry Ladizinski is a former employee of AbbVie and may hold AbbVie stock and/or stock options. He is a current employee of ONE Pharmaceuticals. Jonathan I. Silverberg receives consulting fees from AbbVie, Anacor Pharmaceuticals, GlaxoSmithKline, Lilly, Pfizer, Procter & Gamble, MedImmune, and Regeneron. He serves as an investigator in trials sponsored by Celgene, GlaxoSmithKline, Lilly, Regeneron, and Roche.
: The independent ethics committee or institutional review board at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment (Supplementary Material Table ). The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent to participate in this study before screening.